These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 39284337)

  • 1. Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study.
    Iliopoulos O; Iversen AB; Narayan V; Maughan BL; Beckermann KE; Oudard S; Else T; Maranchie JK; Goldberg CM; Fu W; Perini RF; Liu Y; Linehan WM; Srinivasan R; Jonasch E
    Lancet Oncol; 2024 Oct; 25(10):1325-1336. PubMed ID: 39284337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral Hypoxia-Inducible Factor 2α Inhibitor Belzutifan in Ocular von Hippel-Lindau Disease: Subgroup Analysis of the Single-Arm Phase 2 LITESPARK-004 Study.
    Wiley HE; Srinivasan R; Maranchie JK; Chhablani J; Iversen ABB; Kruse A; Jonasch E; Gombos DS; Else T; Demirci H; Maughan BL; Hartnett ME; Coleman HR; Fu W; Perini RF; Liu Y; Linehan WM; Chew EY;
    Ophthalmology; 2024 Nov; 131(11):1324-1332. PubMed ID: 38849055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Belzutifan for von Hippel-Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study.
    Else T; Jonasch E; Iliopoulos O; Beckermann KE; Narayan V; Maughan BL; Oudard S; Maranchie JK; Iversen AB; Goldberg CM; Fu W; Perini RF; Liu Y; Linehan WM; Srinivasan R
    Clin Cancer Res; 2024 May; 30(9):1750-1757. PubMed ID: 38393723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.
    Jonasch E; Donskov F; Iliopoulos O; Rathmell WK; Narayan VK; Maughan BL; Oudard S; Else T; Maranchie JK; Welsh SJ; Thamake S; Park EK; Perini RF; Linehan WM; Srinivasan R;
    N Engl J Med; 2021 Nov; 385(22):2036-2046. PubMed ID: 34818478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The outcome of central nervous system hemangioblastomas in Von Hippel-Lindau (VHL) disease treated with belzutifan: a single-institution retrospective experience.
    Zamarud A; Marianayagam NJ; Park DJ; Yener U; Yoo KH; Meola A; Chang SD
    J Neurooncol; 2023 Nov; 165(2):373-379. PubMed ID: 37955759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Belzutifan in adults with VHL-associated central nervous system hemangioblastoma: a single-center experience.
    Neth BJ; Webb MJ; White J; Uhm JH; Pichurin PN; Sener U
    J Neurooncol; 2023 Aug; 164(1):239-247. PubMed ID: 37450072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repurposing propranolol as a drug for the treatment of retinal haemangioblastomas in von Hippel-Lindau disease.
    Albiñana V; Escribano RMJ; Soler I; Padial LR; Recio-Poveda L; Villar Gómez de Las Heras K; Botella LM
    Orphanet J Rare Dis; 2017 Jun; 12(1):122. PubMed ID: 28662711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study.
    Choueiri TK; McDermott DF; Merchan J; Bauer TM; Figlin R; Heath EI; Michaelson MD; Arrowsmith E; D'Souza A; Zhao S; Roy A; Perini R; Vickery D; Tykodi SS
    Lancet Oncol; 2023 May; 24(5):553-562. PubMed ID: 37011650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Belzutifan: a novel therapeutic for the management of von Hippel-Lindau disease and beyond.
    Curry L; Soleimani M
    Future Oncol; 2024; 20(18):1251-1266. PubMed ID: 38639572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of molecular genetic analysis of the VHL gene in patients with haemangioblastomas of the central nervous system.
    Gläsker S; Bender BU; Apel TW; Natt E; van Velthoven V; Scheremet R; Zentner J; Neumann HP
    J Neurol Neurosurg Psychiatry; 1999 Dec; 67(6):758-62. PubMed ID: 10567493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors.
    Fallah J; Brave MH; Weinstock C; Mehta GU; Bradford D; Gittleman H; Bloomquist EW; Charlab R; Hamed SS; Miller CP; Dorff SE; Chambers WA; Mixter BD; Dinin J; Pierce WF; Ricks TK; Tang S; Donoghue M; Pazdur R; Amiri-Kordestani L; Ibrahim A; Beaver JA
    Clin Cancer Res; 2022 Nov; 28(22):4843-4848. PubMed ID: 35727604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial.
    Jonasch E; McCutcheon IE; Gombos DS; Ahrar K; Perrier ND; Liu D; Robichaux CC; Villarreal MF; Weldon JA; Woodson AH; Pilie PG; Fuller GN; Waguespack SG; Matin SF
    Lancet Oncol; 2018 Oct; 19(10):1351-1359. PubMed ID: 30236511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation and Management of Apparently Sporadic Central Nervous System Haemangioblastoma for Evidence of Von Hippel-Lindau Disease.
    Furness H; Salfity L; Devereux J; Halliday D; Hanson H; Ruddy DM; Uk Vhl Study Group ; Shah N; Sultana G; Woodward ER; Sandford RN; Snape KM; Maher ER
    Genes (Basel); 2021 Sep; 12(9):. PubMed ID: 34573396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The road to systemic therapy in von Hippel-Lindau (VHL) disease: Are we there yet?
    Shepherd STC; Drake WM; Turajlic S
    Eur J Cancer; 2023 Mar; 182():15-22. PubMed ID: 36708612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurological applications of belzutifan in von Hippel-Lindau disease.
    Zhang Y; Nguyen CC; Zhang NT; Fink NS; John JD; Venkatesh OG; Roe JD; Hoffman SC; Lesniak MS; Wolinsky JP; Horbinski C; Szymaniak BM; Buerki RA; Sosman JA; Shenoy NK; Lukas RV
    Neuro Oncol; 2023 May; 25(5):827-838. PubMed ID: 36215167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Belzutifan: First Approval.
    Deeks ED
    Drugs; 2021 Nov; 81(16):1921-1927. PubMed ID: 34613603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurosurgical Implications of Targeting Hypoxia-Inducible Factor 2α in Hemangioblastomas with Belzutifan.
    Pumford AD; Bauman M; Bouchal S; Riviere-Cazaux C; Jusue-Torres I; Hong S; Neth BJ; Sener U; Parney IF
    World Neurosurg; 2024 Oct; 190():291-296. PubMed ID: 39094939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Innovative solutions? Belzutifan therapy for hemangioblastomas in Von Hippel-Lindau disease: A systematic review and single-arm meta-analysis.
    Palavani LB; Camerotte R; Vieira Nogueira B; Ferreira MY; Oliveira LB; Pari Mitre L; Coelho Nogueira de Castro W; Canto Gomes GL; Fabrini Paleare LF; Batista S; Fim Andreão F; Bertani R; Dias Polverini A
    J Clin Neurosci; 2024 Oct; 128():110774. PubMed ID: 39128437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Belzutifan, HIF-2α Inhibitor, and Clear Cell Renal Cell Carcinoma With Somatic Von-Hippel-Lindau Loss-of-Function Mutation.
    Chan KH; Li N; Lador R; Amsbaugh M; Gonzalez A; Cen P
    J Investig Med High Impact Case Rep; 2024; 12():23247096241231641. PubMed ID: 38344974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Belzutifan: A Narrative Drug Review.
    Visweswaran V; Pavithran K
    Curr Drug Res Rev; 2022; 14(2):88-95. PubMed ID: 35366789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.